Bristol-Myers
Squibb Company (NYSE: BMY) announced today that the Company has
suspended study drug administration in an ongoing Phase II study of
BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B)
inhibitor in development for the treatment of hepatitis C. This
voluntary action was taken to protect patient safety based on the
emergence of a serious safety issue. The cause of the safety issue and
any potential relationship to study drug are unknown at this time.
With patient safety as the priority, the Company is undertaking an
immediate assessment of all patients in the study and following an
evaluation of the patient data, will take appropriate actions.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb CompanyMedia:Sonia Choi, 609-252-5132sonia.choi@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.comorTimothy Power, 609-252-7509timothy.power@bms.com